Key result
Thrombolysis did not reduce mortality compared with intravenous heparin alone in patients with acute submassive pulmonary embolism.
Why the study?
Does systemic thrombolysis compared with intravenous heparin alone reduce mortality and recurrent pulmonary embolism without increasing bleeding risk in adults with acute submassive pulmonary embolism?
Meta-Analysis (n=594)
Double-blind in 5 of 7 trials
Randomized controlled trials included (specific random methods mentioned in 4 of 7 trials)
Does systemic thrombolysis compared with intravenous heparin alone reduce mortality and recurrent pulmonary embolism without increasing bleeding risk in adults with acute submassive pulmonary embolism?
Answers are grounded in this paper and cite their sources.
In patients with acute submassive pulmonary embolism, systemic thrombolysis compared with heparin alone did not significantly reduce mortality or recurrent PE and did not increase major bleeding, though it significantly increased minor bleeding and larger trials are needed due to limited sample size.
PURPOSE: The aim of this systematic review was to evaluate the efficacy and safety of thrombolytic treatment in patients with submassive pulmonary embolism (PE). METHODS: An electronic search was carried out based on the databases from MEDLINE, Embase, Science Citation Index (SCI), and the Cochrane Library. We included prospective, randomized, and clinical trials in thrombolysis with heparin alone in adults who had evidence of right ventricular dysfunction and normotension. The main endpoints consist of mortality, recurrent PE, and bleeding risk. The relative risk (RR) and the relevant 95% confidence intervals were determined by the dichotomous variable. RESULTS: Only seven studies involving 594 patients met the inclusion criteria for further review. The cumulative effect of thrombolysis, compared with intravenous heparin, demonstrated no statistically significant difference in mortality (2.7% versus 4.3%; RR=0.64 [0.29-1.40]; P=0.27) or recurrent PE (2% versus 5%; RR=0.44 [0.19-1.05]; P=0.06). Thrombolytic therapy did not increase major hemorrhage compared with intravenous heparin (4.5% versus 3.3%; RR=1.16 [0.51-2.60]; P=0.73), but it was associated with an increased minor hemorrhage (41% versus 9%; RR=3.91 [1.46-10.48]; P=0.007). CONCLUSION: Compared with heparin alone, neither mortality nor recurrent PE is reduced by thrombolysis in patients with submassive PE, and it does not reveal an increasing risk of major bleeding. In addition, thrombolysis also produces the increased risk of minor bleeding; however, no sufficient evidence verifies the thrombolytic benefit in this review, because the number of patients enrolled in the trials is limited. Therefore, a large, double-blind clinical trial is required to prove the outcomes of this meta-analysis.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2014) conducted a meta-analysis in Acute submassive pulmonary embolism (n=594). Systemic intravenous thrombolysis (alteplase in 6 trials, tenecteplase in 1 trial) followed by heparin and oral warfarin vs. Intravenous heparin alone (adjusted to maintain aPTT at 2.0-2.5 times normal) followed by oral warfarin was evaluated on All-cause mortality (RR 0.64, 95% CI 0.29-1.40, p=0.27). Thrombolysis did not reduce mortality compared with intravenous heparin alone in patients with acute submassive pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: